Pembrolizumab Phase 3 Trials

Anonymous

Tell me phase 3 trials related to pembrolizumab conducted in United States

Clinical Trials Expert logo
Clinical Trials Expert

Here are three Phase 3 clinical trials related to Pembrolizumab conducted in the United States:

  1. Trial ID: NCT04624204

    • Title: Placebo-controlled Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)
    • Sponsor: Merck Sharp & Dohme LLC
    • Status: Recruiting (as of 2023-12-28)
    • Overview: This trial is an interventional study designed to evaluate the efficacy of Pembrolizumab in combination with concurrent chemoradiation therapy followed by Pembrolizumab with or without Olaparib, compared to concurrent chemoradiation therapy alone in participants with newly diagnosed treatment-naïve limited-stage Small Cell Lung Cancer (LS-SCLC). The trial includes various intervention arms such as Pembrolizumab, Olaparib, and standard therapies.

  2. Trial ID: NCT04736706

    • Title: A Study of Pembrolizumab in Combination With Belzutifan and Lenvatinib, or Pembrolizumab/Quavonlimab in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)
    • Sponsor: Merck Sharp & Dohme LLC
    • Status: Recruiting (as of 2024-01-05)
    • Overview: This open-label, randomized Phase 3 study assesses the efficacy and safety of Pembrolizumab in combination with Belzutifan and Lenvatinib, or Pembrolizumab/Quavonlimab in combination with Lenvatinib, versus Pembrolizumab and Lenvatinib, as first-line treatment in participants with advanced clear cell renal cell carcinoma (ccRCC).

  3. Trial ID: NCT05727904

    • Title: Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma
    • Sponsor: Iovance Biotherapeutics, Inc.
    • Status: Recruiting (as of 2024-01-08)
    • Overview: This Phase 3 study is a multicenter, randomized, open-label trial designed to evaluate the efficacy and safety of the Lifileucel regimen in combination with Pembrolizumab compared to Pembrolizumab monotherapy in participants with untreated, unresectable or metastatic melanoma.

These trials focus on various cancers and investigate the efficacy of Pembrolizumab in combination with other treatments or as a standalone therapy.